Form 4: Amylyx Co-CEO Exercises Options, Sells Shares Under 10b5-1 Plan

Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen exercised stock options and subsequently sold shares to cover costs and tax obligations, as per a pre-arranged 10b5-1 plan.

Summary

• Joshua B. Cohen, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX), reported transactions involving the company's common stock.
• On January 15, 2026, Cohen acquired 197,182 shares of common stock through the exercise of stock options at an exercise price of $7.57 per share.
• On the same day, he disposed of 136,193 shares of common stock at a weighted average price of $13.5895 per share. These sales were executed to cover option costs and tax obligations.
• On January 16, 2026, Cohen acquired an additional 2,818 shares of common stock via option exercise at $7.57 per share.
• Also on January 16, 2026, he sold 1,974 shares of common stock at a weighted average price of $13.8293 per share, also for cost and tax coverage.
• All sales were conducted pursuant to a preset sales plan adopted on November 12, 2025, under Rule 10b5-1(c).
• The stock options exercised were fully vested and exercisable, with an expiration date of February 19, 2026.
• Following these transactions, Cohen's direct beneficial ownership of common stock was 3,379,465 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The exercise of options indicates confidence, while the subsequent sale is a routine, pre-planned event to cover costs and taxes, not necessarily a negative signal about the company's future.

Positives

• The exercise of stock options indicates a long-term commitment and belief in the company's value by a key executive.
• The exercise price of $7.57 is significantly lower than the sale prices ($13.5895 and $13.8293), indicating a personal financial gain for the executive.
• The transactions were conducted under a Rule 10b5-1 plan, which suggests pre-planning and reduces concerns about opportunistic insider trading.

Negatives

• The sale of shares by a Co-CEO, even for tax purposes, can sometimes be perceived negatively by investors as it reduces the executive's direct equity stake.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide specific industry context. However, as a biotechnology company, executive stock transactions are closely watched for insights into management's confidence, especially given the capital-intensive nature and regulatory hurdles common in the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the option exercise as a positive sign of executive confidence, while the sales are generally understood as routine for tax and cost coverage, minimizing negative perception.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The exercised stock options are due to expire on February 19, 2026.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Insider Trading, Stock Options, Executive Compensation, Share Sale, Joshua B. Cohen, 10b5-1 Plan, Biotechnology